乳腺癌新辅助化疗残余肿瘤组织病理信息与预后分析

doi:10.11904/j.issn.1002-3070.2020.03.007

摘要/Abstract

摘要： 目的探讨乳腺癌新辅助化疗前后肿瘤组织病理信息的变化及对预后的影响。方法对2014年1月—2016年5月就诊于辽宁省肿瘤医院乳腺外科并行规范乳腺癌新辅助化疗的177例患者回顾性分析,探讨乳腺癌新辅助化疗前后肿瘤组织病理信息的变化,并分析残余肿瘤组织病理信息对无病生存期(DFS)和总生存期(OS)的影响。结果 177例乳腺癌患者中位随访时间为37个月,37个月无病生存率和总生存率分别为84.0%和95.0%,4年无病生存率和总生存率分别为79.7%和81.1%。新辅助化疗后乳腺癌患者的DFS独立危险因素为原始T分期、原始N分期、存在脉管侵袭、新辅助化疗后Ki-67增加。OS的独立危险因素为原始T分期、原始N分期。而新辅助化疗前后ER状态的改变、PR状态的改变、HER-2状态的改变与患者预后无关(P＞0.05)。结论乳腺癌新辅助化疗前后分子生物学指标ER、PR、HER-2、Ki-67可以发生改变,但与乳腺癌患者预后无关。原始肿瘤T分期、原始肿瘤N分期、存在脉管侵袭和Ki-67增加是影响乳腺癌患者DFS的危险因素。原始肿瘤T分期、原始肿瘤N分期是影响乳腺癌患者OS的危险因素。

关键词: 乳腺癌, 新辅助化疗, 分子生物学指标, 预后

Abstract: Objective The aim of this study was to explore the changes of tumor histopathological information of breast cancer before and after neoadjuvant chemotherapy and its effect on prognosis.Methods A retrospective analysis of 177 patients with breast cancer undergoing neoadjuvant chemotherapy who were admitted to the Department of Breast Surgery of Liaoning Cancer Hospital from January 2014 to May 2016 was conducted to determine the changes of tumor histopathological information before and after neoadjuvant chemotherapy.The effects of residual tumor histopathological information on disease-free survival(DFS)and overall survival(OS)were analyzed.Results The median follow-up time of 177 breast cancer patients was 37 months.The 37-month disease-free survival rate and overall survival rate were 84.0% and 95.0%,respectively.The 4-year disease-free survival rate and overall survival rate were 79.7% and 81.1%,respectively.The independent risk factors of DFS in breast cancer patients after neoadjuvant therapy were the original T stage,the original N stage,the presence of vascular invasion,and increasing Ki-67 after neoadjuvant chemotherapy.The independent risk factors of OS were the original T stage and the original N stage.The changes of ER status,PR status and HER-2 status before and after neoadjuvant chemotherapy were not related to the prognosis of patients(P＞0.05).Conclusion The molecular biological indexes ER,PR,HER-2 and Ki-67 can be changed for breast cancer before and after neoadjuvant chemotherapy,but it has nothing to do with the prognosis of breast cancer patients.The T stage of the original tumor,the N stage of the original tumor,the presence of vascular invasion and the increasing Ki-67 are the risk factors that affect the DFS of patients with breast cancer.The original tumor T stage and N stage are the risk factors that affect the OS of patients with breast cancer.

Key words: Breast cancer, Neoadjuvant chemotherapy, Molecular biological indicators, Prognosis

中图分类号:

R73-36

谢贤鑫, 韦军, 邱佳鑫, 王聪, 姜大庆. 乳腺癌新辅助化疗残余肿瘤组织病理信息与预后分析[J]. 实用肿瘤学杂志, 2020, 34(3): 225-231.

XIE Xianxin,WEI Jun,QIU Jiaxin,WANG Cong,JIANG Daqing. Analysis of histopathological information and prognosis of residual tumor in neoadjuvant chemotherapy for breast cancer[J]. Journal of Practical Oncology, 2020, 34(3): 225-231.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.03.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I3/225

参考文献

1 Apuri S.Neoadjuvant and adjuvant therapies for breast cancer[J].South Med J,2017,110(10):638-642.
2 周星彤,沈松杰,孙强.中国乳腺癌筛查现状及进展[J].中国医学前沿杂志(电子版),2020,12(3):6-11.
3 Li F,Ma L,Geng C,et al.Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors[J].Pathol Res Pract,2018,214(8):1166-1172.
4 刘欢.乳腺癌新辅助化疗前后分子生物学指标变化及预后分析[D].石家庄:河北医科大学,2018.
5 叶京明,刘荫华.2017年NCCN乳腺癌临床实践指南(第3版)更新与回顾[J].中华医学杂志,2018,98(18):1377-1379.
6 Parinyanitikul N,Lei X,Chavez-Macgregor M,et al.Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes[J].Clin Breast Cancer,2015,15(2):153-160.
7 Li L,Han D,Wang X,et al.Prognostic values of Ki-67 in neoadjuvant setting for breast cancer:a systematic review and meta-analysis[J].Future Oncol,2017,13(11):1021-1034.
8 刘伟,王燕荣,王永兴.新辅助化疗后的病理完全缓解及其对不同分子亚型乳腺癌的预后价值[J].现代肿瘤医学,2018,26(13):2118-2122.
9 Denkert C,Von Minckwitz G,Darb-Esfahani S,et al.Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer:a pooled analysis of 3771 patients treated with neoadjuvant therapy[J].Lancet Oncol,2018,19(1):40-50.
10 吴晶晶,张妍,林琳,等.ER和PR阴性乳腺癌雄激素受体与HER2表达相关性及其临床意义[J].中华肿瘤防治杂志,2016,23(23):1544-1549.
11 Hirata T,Shimizu C,Yonemori K,et al.Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer[J].Br J Cancer,2009,101(9):1529-1536.
12 李国政,庞达.HER2阳性乳腺癌治疗的研究进展[J].实用肿瘤学杂志,2020,34(1):74-78.
13 Yoshida A,Hayashi N,Suzuki K,et al.Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer[J].J Surg Oncol,2017,116(8):1021-1028.
14 Tao M,Chen S,Zhang X,et al.Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer:A meta-analysis[J].Medicine,2017,96(51):e9384.
15 Lee J,Im YH,Lee SH,et al.Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer[J].Cancer Chem Pharm,2008,61(4):569-577.
16 Matsubara N,Mukai H,Fujii S,et al.Different prognostic significance of Ki-67 change between pre-and post-neoadjuvant chemotherapy in various subtypes of breast cancer[J].Breast cancer Res Treat,2013,137(1):203-212.
17 Samuel O,Olayide A,Ganiyu R,et al.Relationship between tumour size and response to neoadjuvant chemotherapy among breast cancer patients in a tertiary center in Nigeria[J].Malawi Med J,2018,30(1):13-16.
18 Wu SG,Li Q,Zhou J,et al.Using the lymph node ratio to evaluate the prognosis of stage Ⅱ/Ⅲ breast cancer patients who received neoadjuvant chemotherapy and mastectomy[J].Cancer Res Treat,2015,47(4):757-764.

[1]	李慧, 庞达. 三阳型乳腺癌的临床病理学特点及辅助治疗[J]. 实用肿瘤学杂志, 2020, 34(3): 262-265.
[2]	王棹, 冯越, 邢丽楠, 张云艳. PLR与恶性肿瘤同步放化疗预后的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 271-275.
[3]	苏文佳, 王树叶. 滤泡性淋巴瘤的预后分层和治疗进展[J]. 实用肿瘤学杂志, 2020, 34(2): 189-192.
[4]	赵云霞, 牛波. LncRNA NBAT1通过调控miR-3664-5p/Caspase 9分子轴对人乳腺癌细胞增殖的影响[J]. 实用肿瘤学杂志, 2020, 34(1): 24-29.
[5]	廖代祥, 郑博, 张彦斌, 于军辉. RRBP1与RABEX-5蛋白在结直肠癌组织中的表达及与临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2020, 34(1): 43-48.
[6]	李国政, 庞达. HER2阳性乳腺癌治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 74-78.
[7]	刘耿淳, 申良方. 血清长链非编码RNA MALAT1和AFAP1-AS1与鼻咽癌临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 513-518.
[8]	曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.
[9]	沈依哲, 郭宝良. 初诊Ⅳ期乳腺癌的局部治疗研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 575-578.
[10]	范晋海, 蒋玉梅, 张静, 白晓静. MAP1A在膀胱癌组织中的表达及其与临床病理特征的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 525-530.
[11]	刘四卫, 崔玥, 孙元元, 胡晶, 张文睿, 曹孟儒. FOXD3在肺癌细胞中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 390-396.
[12]	夏天一, 张博淼, 姚克非, 崔滨滨. PTPN9表达水平与结直肠癌的临床关系研究[J]. 实用肿瘤学杂志, 2019, 33(5): 415-419.
[13]	师镘茹, 鄂明艳. 放疗延迟对乳腺癌不同分子亚型患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 431-435.
[14]	徐亭, 严斐斐, 张纯慧, 张艳桥. 胃癌骨转移患者临床病理与预后分析[J]. 实用肿瘤学杂志, 2019, 33(5): 436-441.
[15]	李磊 , 张清媛. 乳腺癌抗肿瘤血管治疗的临床进展[J]. 实用肿瘤学杂志, 2019, 33(5): 461-465.